Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007933 | 0.86 | FGFR1 (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL7743090 | 0.80 | POLG (0.40) | FGFR1SLC22A6 | |
| SCHEMBL1065338 | 0.77 | FGFR1 (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL27503114 | 0.77 | FGFR1 (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL440453 | 0.76 | PDE3A (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL28515026 | 0.74 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL15798503 | 0.73 | PDE3A (0.33) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL8910525 | 0.73 | FGFR1 (0.36) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL5356639 | 0.73 | FGFR1 (0.39) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL1629582 | 0.71 | FGFR1 (0.44) | FGFR1LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20140005147-A1 | DNA POLYMERASE INHIBITORS COMPOSITION AND METHODS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-01-02 | — | — | US | disclosed |
| US-8524690-B2 | DNA polymerase inhibitors composition and methods | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2374890-B1 | Fen-1 endonucleases, mixtures and cleavage methods | THIRD WAVE TECH INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8288093-B2 | Forming a nucleic acid invasive cleavage structure on a target sequence and cleaving the nucleic acid invasive cleavage structure in a site-specific manner; fluorescence in-situ hybridization detection of cytomegalo virus | THIRD WAVE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2058407-B1 | Invasive cleavage of nucleic acids | THIRD WAVE TECH INC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2354252-B1 | Invasive cleavage of nucleic acids | THIRD WAVE TECH INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8182991-B1 | FEN-1 endonucleases, mixtures and cleavage methods | THIRD WAVE TECHNOLOGIES, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-6090543-A | DETECTING THE PRESENCE OF A TARGET NUCLEIC ACID MOLECULE BY MIXING TOGETHER CLEAVAGE MEANS, TARGET NUCLEIC ACID, AND COMPLEMENTARY OLIGONUCLEOTIDES; THEN DETECTING NON-TARGET CLEAVAGE PRODUCTS | THIRD WAVE TECHNOLOGIES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0994964-A1 | DETECTION OF NUCEIC ACIDS BY MULTIPLE SEQUENTIAL INVASIVE CLEAVAGES | THIRD WAVE TECHNOLOGIES, INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0966542-A1 | FEN-1 ENDONUCLEASES, MIXTURES AND CLEAVAGE METHODS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| US-6001567-A | SCREENING FOR TARGET RNA MOLECULE; PROVIDING NUCLEASE, TARGET RNA, AND OLIGONUCLEOTIDES, MIXING, ALLOW ANNEALING, SCREEN FOR NON-TARGET CLEAVAGE PRODUCTS, ELECTROPHORETIC SEPARATION AND VISUALIZATION OF PRODUCTS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5994069-A | FORMING NUCLEIC ACID CLEAVAGE STRUCTURE ON TARGET SEQUENCE AND CLEAVING THE NUCLEIC ACID IN A SITE SPECIFIC MANNER USING STRUCTURE SPECIFIC 5'NUCLEASES THEN ANNEALING COMPLEMENTARY OLIGONUCLEOTIDES TO DETECT TARGET NUCLEIC ACID | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5985557-A | TARGET NUCLEIC ACID AND OLIGONUCLEOTIDE MIXTURE | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0904286-A1 | INVASIVE CLEAVAGE OF NUCLEIC ACIDS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1998042873-A1 | DETECTION OF NUCEIC ACIDS BY MULTIPLE SEQUENTIAL INVASIVE CLEAVAGES | THIRD WAVE TECHNOLOGIES, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998023774-A1 | FEN-1 ENDONUCLEASES, MIXTURES AND CLEAVAGE METHODS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| WO-1997027214-A1 | INVASIVE CLEAVAGE OF NUCLEIC ACIDS | THIRD WAVE TECHNOLOGIES, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | FGFR1 3847/4885LMNA 2267/4885THRB 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.